Navigation Links
CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of,Action for Ranexa

-- New Preclinical Information May Correlate with Clinical HbA1c Reductions Observed in Phase 3 CARISA and MERLIN TIMI-36 Clinical Trials --

PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that researchers have completed preliminary preclinical studies showing that ranolazine increased glucose stimulated insulin secretion in pancreatic beta cells. In separate experiments using preclinical models of insulin resistance, ranolazine also improved glucose homeostasis.

These data could illustrate an underlying first in class mechanism of action for the statistically significant reductions in HbA1c levels observed with Ranexa in cardiovascular patients with diabetes from the phase 3 CARISA (n=189 with angina and diabetes) and MERLIN TIMI-36 (n=2,220 with acute coronary syndromes and diabetes) clinical trials.

In CARISA (Combination Assessment of Ranolazine in Stable Angina), Ranexa (ranolazine extended release tablets) reduced HbA1c levels by an average of up to 0.7 percentage points in angina patients with diabetes. The reduction in HbA1c was not associated with increased hypoglycemia.

"Preclinical studies have shown that Ranexa inhibits the late sodium current in cardiac cells. Potentially, the sodium channels present in pancreatic beta cells may play a role in the secretion of insulin," said Luiz Belardinelli, M.D., senior vice president of pharmacological translational and biomedical research and a distinguished fellow of cardiovascular science at CV Therapeutics.

The company plans to submit data from these new preclinical experiments for publication later this year.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of ca
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
4. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
5. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
6. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
7. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Post Your Comments:
(Date:8/20/2014)... , August 20, 2014 ... of Glenmark Pharmaceuticals Limited India (GPL), announces the ... a novel clinical development candidate, GBR 1302, a ... developed by the Glenmark Biologics Research Centre located ... GBR 1302 is based on Glenmark,s innovative BEAT ...
(Date:8/19/2014)... -- The Alabama Supreme Court, in a 6-3 decision on August ... mislead doctors into believing that prescription medicines the companies market ... Wyeth, and the decision came after the Supreme Court ruled ... Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a clear ...
(Date:8/19/2014)... 2014 Minimally Invasive Devices Inc. (MID), a ... announced today that Mitsubishi Corporation has formally agreed to ... in Japan . MID anticipates that ... Japan in the second half of 2015. ... for Karl Storz GMBH & Co. (endoscopic instruments and ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2
... RIDGE, N.J., Nov. 16, 2010 Regado Biosciences, Inc., ... aptamers with active control agents, announced that Thomas J. ... abstract at the AHA Scientific Sessions meeting on November ... The abstract, entitled "RB006, a Direct Factor ...
... 16, 2010 Reportlinker.com announces that a new ... Global Ambulatory & Bathroom Aids ... This report analyzes the worldwide markets for ... Thousand Units by the following Product Segments: Ambulatory ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 2Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 3Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 4Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 2Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 3Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 4Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 5Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 6Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 7Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 8Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 9Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 10Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 11Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 12Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 13Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 14Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 15Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 16Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 17Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 18Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 19Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 20Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 21Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 22Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 23Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 24Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 25Reportlinker Adds Global Ambulatory & Bathroom Aids Industry 26
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 According ... filed on August 7 in the multicounty litigation (MCL) ... (IN RE DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), ... MCL have been dismissed without prejudice. The cases enumerated ... process of being resolved.” The Rottenstein Law Group LLP, ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the global ... grow to $15.2 billion by 2019, with a ... Increasing industrialization is driving significant growth across ... range of industrial applications such as military and ...
(Date:8/20/2014)... Mateo, CA (PRWEB) August 20, 2014 ... newest product—the Really Little Green Pouch —to meet ... to feed babies and toddlers homemade foods. , ... Little Green Pouch co-founder Maggie Crawford. She continues, ... kids, to limit exposure to things like pesticides and ...
(Date:8/20/2014)... Pittsburgh, PA (PRWEB) August 20, 2014 ... to clean the mouth in an optimal manner without ... an inventor from Vacaville, Calif. , The patent-pending DR. ... the tongue and teeth thoroughly. It promotes good oral ... to use two different devices. Convenient, compact, affordable, eco-friendly ...
(Date:8/20/2014)... Tumour Research has been chosen by Plymouth University to ... launched in April 2009 to raise awareness of, and ... outcomes for brain tumour patients. , A range of ... funds for the charity, and members of staff and ... encouraged to donate, fundraise and volunteer. The involvement of ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:Plymouth University chooses Brain Tumour Research as official charity 2
... Preventative Services Task Force,s (USPSTF) recommendation to no longer ... has begun to negatively affect the number of yearly ... the benefits of early detection. After the USPSTF delivered ... of Colorado saw a significant drop in mammograms in ...
... Mayo Clinic researchers have discovered two mutations responsible for ... ago. The researchers say their study -- appearing in ... neural pathway that may help understand a variety of ... now because of Next Generation genomic sequencing technology," says ...
... bursts of sleep in infants are linked with growth spurts, new ... daily sleep records for their infants (14 girls, nine boys), who ... researchers analyzed the total of 5,798 daily sleep records and also ... sleep, with the amount of sleep over a 24-hour period increasing ...
... can be quite jarring for a parent or caregiver to ... child roaming around the backseat free of their safety restraints. ... researchers reveals that most children who first unbuckle were age ... vehicle is in motionputting them at a 3.5-fold increased risk ...
... -- A drug commonly used to treat kidney cancer may ... study published in the May issue of the Journal ... the action of mammalian target of rapamycin (mTOR), a protein ... used to treat advanced renal cell carcinoma. But researchers ...
... Medical costs for children and teens with diabetes are six ... States, a new study finds. Researchers from the U.S. ... made in 2007 for nearly 50,000 youth aged 19 and ... youth with diabetes were $9,061, compared with $1,468 for those ...
Cached Medicine News:Health News:New studies show negative effects from revised mammography recommendation for women, ages 40-49 2Health News:Mayo Clinic finds new genetic cause of neurodegeneration 2Health News:Extra Sleep in Infants Seems to Signal Growth Spurts 2Health News:Little fingers, big trouble: Yale study sheds light on child self-unbuckling 2Health News:Renal cancer drug temsirolimus shows promise against mesothelioma 2
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
5L...
... is precision, ergonomics, and value!, ... with soft non-slip, contoured handle , ... light plunger spring action , Completely ... without the need for recalibration , ...
Medicine Products: